Q-omics provides the consensus-scored TCHHL1 profile across patient tissues and cancer cell-line models. TCHHL1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TCHHL1 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, TCHHL1 RNA expression shows 6,313 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, LUSC, and STAD as cancer lineages where TCHHL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCHHL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCHHL1 survival associations across molecular data types. TCHHL1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCHHL1 RNA expression–survival associations across cancer types. High TCHHL1 expression shows unfavorable associations in BLCA, SCLC, KIRC, UCEC, LIHC and TGCT. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TCHHL1 RNA expression.
This table summarizes TCHHL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TCHHL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCHHL1 shows higher tumor expression in LUSC and LUAD. The LUSC box plot shows higher TCHHL1 RNA expression in tumor versus normal tissue (log2 FC = +0.173, t-test p < 0.001).
This table shows molecular features associated with TCHHL1 in patient tissues and cancer cell lines. In patient samples, TCHHL1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TCHHL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
